MDGLHIGH SIGNALFINANCIAL10-K

MDGL shows dramatic deterioration across key financial metrics with total debt increasing 189% and SG&A expenses nearly doubling, despite some improvement in operating cash flow burn rate.

The massive increases in debt (189%), interest expense (263%), and SG&A costs (87%) suggest significant operational scaling challenges or distress, particularly concerning given the company's continued negative operating cash flow of $189.6M. While the improved cash burn rate and higher accounts receivable indicate some revenue growth likely from Rezdiffra launches, the overall financial picture shows a company under substantial strain.

Comparing 2026-02-19 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reveal a company experiencing dramatic cost inflation with SG&A expenses nearly doubling to $813.8M and total debt tripling to $339.9M, driving interest expense up 263%. While accounts receivable growth of 150% and improved operating cash flow burn (from -$455.6M to -$189.6M) suggest meaningful revenue generation likely from Rezdiffra commercialization, the company remains cash flow negative with significantly higher leverage and operating costs. The combination of massive debt increases, expense inflation, and continued cash burn creates a precarious financial position that requires close monitoring.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+262.8%
$3.5M$12.7M

Interest expense surged 262.8% — significant debt increase or rising rates materially impacting earnings.

Total Debt
Balance Sheet
+189.1%
$117.6M$339.9M

Debt increased 189.1% — substantial leverage increase; assess whether deployed for growth or covering losses.

Accounts Receivable
Balance Sheet
+149.9%
$53.8M$134.5M

Receivables surged 149.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Liabilities
Balance Sheet
+128.2%
$287.9M$656.9M

Liabilities grew 128.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Inventory
Balance Sheet
+119.7%
$34.1M$74.8M

Inventory surged 119.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Cash & Equivalents
Balance Sheet
+98.7%
$100.0M$198.7M

Cash position surged 98.7% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
+87.1%
$435.1M$813.8M

SG&A up 87.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+83.3%
$169.3M$310.3M

Current liabilities surged 83.3% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-68.1%
$1.5M$467K

Capex reduced 68.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+58.4%
-$455.6M-$189.6M

Operating cash flow surged 58.4% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-26
ADDED
As of February 12, 2026, the registrant had 22,939,969 shares of common stock outstanding.
You should not place undue reliance on any such forward-looking statements.
You should carefully consider all of the information in this report and, in particular, the following principal risks and all of the other specific factors described in Item 1A.
of this report, Risk Factors, before deciding whether to invest in our company.
We obtained accelerated approval in the United States and conditional marketing authorization in the European Union ( EU ) for Rezdiffra, and we are subject to certain post-marketing commitments.
+7 more — sign up free →
REMOVED
As of February 21, 2025, the registrant had 22,080,246 shares of common stock outstanding.
You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made.
Before you invest in our securities, you should read the following summary together with the more detailed description of material risks described in the section titled Risk Factors in Part I, Item 1A of this Annual Report and the other information contained in this Annual Report.
We obtained regulatory approval of Rezdiffra in the United States through an accelerated approval process, and we are subject to certain post-marketing commitments.
We may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →